Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920181 | 1.00 | AKR1C3 (0.44) | AKR1C3NFE2L2PTGS1PTGS2POLB | |
| SCHEMBL1920614 | 1.00 | AKR1C3 (0.44) | AKR1C3NFE2L2PTGS1PTGS2POLB | |
| SCHEMBL1431701 | 0.87 | AKR1C3 (0.46) | AKR1C3NFE2L2CES2CES1APEX1 | |
| SCHEMBL1786006 | 0.84 | AKR1C3 (0.43) | AKR1C3APEX1DHODH | |
| SCHEMBL28791756 | 0.84 | AKR1C3 (0.43) | AKR1C3PTGS1PTGS2APEX1DHODH | |
| SCHEMBL1786005 | 0.84 | AKR1C3 (0.43) | AKR1C3APEX1DHODH | |
| SCHEMBL3033598 | 0.83 | AKR1C3 (0.42) | AKR1C3PTGS2POLBMAPTAPEX1 | |
| SCHEMBL3033600 | 0.83 | AKR1C3 (0.42) | AKR1C3PTGS2POLBMAPTAPEX1 | |
| SCHEMBL7094608 | 0.80 | CES2 (0.42) | AKR1C3CES2CES1APEX1DHODH | |
| SCHEMBL7094606 | 0.80 | CES2 (0.42) | AKR1C3CES2CES1APEX1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20080200731-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7381832-B2 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| US-20050234264-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6956129-B2 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-10-18 | — | — | US | disclosed |
| EP-1362025-A2 | POLYHALOGEN-SUBSTITUTED CINNAMIC ACIDS AND CINNAMIC ACID DERIVATIVES AND A METHOD FOR PRODUCING THE SAME | Bayer Aktiengesellschaft (DE) | 2003-11-19 | — | — | EP | disclosed |
| EP-0910380-B1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002066411-A2 | POLYHALOGEN-SUBSTITUTED CINNAMIC ACIDS AND CINNAMIC ACID DERIVATIVES AND A METHOD FOR PRODUCING THE SAME | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-29 | — | — | WO | disclosed |
| US-20020115885-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | US | disclosed |
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6063818-A | Substituted benzylidene indenyl formamides, acetamides and propionamides | CELL PATHWAYS INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-5998477-A | MIXTURE OF DRUG AND CARRIER | CELL PATHWAYS INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0910380-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | Cell Pathways, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997047303-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997047295-A1 | SUBSTITUTED METHOXY BENZYLIDENE INDENYL-ACETIC AND PROPIONIC ACIDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | AKR1C3 170/4885NFE2L2 2905/4885PTGS1 1681/4885 |
| US-20050234264-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | DDT, DDC, NISCH | AKR1C3 1058/4885NFE2L2 929/4885PTGS1 2373/4885 |
| US-20080200731-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | DDT, DDC, NISCH | AKR1C3 1058/4885NFE2L2 929/4885PTGS1 2373/4885 |
| US-20020115885-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | DDT, DDC, NISCH | AKR1C3 715/4885NFE2L2 926/4885PTGS1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.